EAN
Prof. George Grossberg discusses the unmet need in agitation associated with Alzheimer's disease, the rationale behind the phase 3 ADAGIO studies, and the evolving role of biomarkers and caregivers in improving patient care. We spoke with Prof. George Grossberg, Saint Louis ...
Could biomarker-driven Alzheimer’s care widen existing disparities? Lessons from the New IDEAS study
Large real-world study highlights important ethnoracial differences in amyloid positivity and their implications for diagnosis, treatment and clinical trial access As amyloid biomarkers become central to Alzheimer's disease diagnosis and treatment, a new analysis from the New IDEAS (Imaging Dementia—...
We are delighted to announce Dr Carolina Dal Bo as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of research in rare inflammatory disorders of the central nervous system. From falling in love ...
We are delighted to announce Dr Björn Vahsen as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of research in amyotrophic lateral sclerosis and related neurodegenerative diseases Dr Björn Vahsen (Nuffield ...
Dr Joost Smolders discusses the biology of broad rim lesions, their association with faster disability accumulation and how they could help inform future prognostication and treatment strategies in multiple sclerosis. Emerging biomarkers capable of identifying patients at risk of rapid ...
Prof. Lutz Frölich discusses the 48-month Clarity AD open-label extension, including long-term efficacy, clinical meaningfulness, safety and what these findings could mean for patients eligible for lecanemab in Europe. At the European Academy of Neurology (EAN) Congress 2026, Prof. Lutz ...
Both intracerebral hemorrhage and ischemic stroke continue to be the leading causes of disability and the second leading causes of death worldwide.1,2 The burden is largest in low- and middle-income countries, which have seen rapid recent population growth. Large vessel ...
In this narrative review, we aim to introduce the reader to the history of calcitonin gene-related peptide (CGRP) discovery and its involvement in migraine pathophysiology. We will then look at drug development and clinical trials in migraine. We will additionally ...
Recent omaveloxolone updates include progress in the phase 3 BRAVE study, development of a liquid-ready formulation and evolving reimbursement discussions across multiple regions Phase 3 BRAVE study advances pediatric development in Friedreich’s ataxia Biogen is continuing to expand the clinical development ...
Your clinical career is shaped not only by what you know, but by who helps you navigate what comes next. Join us for the final episode in our mini-series exploring non-clinical skills that can help you thrive in your clinical ...
Findings from AAN 2026 highlight a potential “survival paradox” associated with GLP-1 analogue use in older adults with diabetes At American Academy of Neurology 2026, Isaac Thorman (New York Medical College, Valhalla, NY, USA) presented new real-world data exploring the relationship between ...
ESOC 2026 highlights: Blood pressure management, neuroprotection and widening inequalities shape stroke discussions in Maastricht #VoiceOfStroke [caption id="attachment_101685" align="alignright" width="300"] © European Stroke Organisation #VoiceOfStroke[/caption] At the 12th European Stroke Organisation Conference 2026, late-breaking clinical trial data and population-level analyses ...
New international data support rapid aquaporin-4 antibody testing to improve earlier diagnosis and access to care in NMSOD Accurate and timely antibody testing remains central to improving outcomes in neuromyelitis optica spectrum disorder (NMOSD), where early diagnosis can help prevent ...
New X-TOLE2 findings highlight the potential of azetukalner in treatment-resistant focal epilepsy Despite a growing number of available therapies, many people with Focal epilepsy continue to experience uncontrolled seizures, highlighting the ongoing need for more effective and better tolerated treatment ...
Prof. Michael Levy highlights the first positive phase 3 trial in MOGAD and what it could mean for future standards of care. Relapse prevention remains one of the greatest unmet needs in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), where recurrent inflammatory ...
Six key oral presentations from this year’s ADI meeting on diagnosis, therapies and innovation in care Conference coverage | Held from 14–16 April, the 37th Global Conference of Alzheimer’s Disease International (ADI), Lyon, France, brought together global expertise and lived ...
New Phase 2b data highlight the potential of targeting synaptic dysfunction to slow disease progression in dementia with Lewy bodies Dementia with Lewy bodies (DLB) remains an area of high unmet need, with no approved disease-modifying therapies and significant clinical ...
touchNEUROLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
